Humacyte financials
$0.5327−2.65%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $2.0M | $0.00 | $0.00 | $1.6M | $1.3M |
| Gross profit | -$7.7M | $0.00 | $0.00 | $1.6M | $1.3M |
| Gross margin | −376.1% | — | — | 100.0% | 100.0% |
| Operating income | -$108.1M | -$114.4M | -$100.0M | -$8.8M | -$25.4M |
| Net income | -$40.8M | -$148.7M | -$110.8M | -$12.0M | -$26.5M |
| Net margin | −2003.6% | — | — | −764.5% | −2096.4% |
| Diluted EPS | $-0.26 | $-1.26 | $-1.07 | $-0.12 | $-0.66 |
| EBITDA | -$102.8M | -$109.3M | -$92.3M | -$76.3M | -$72.9M |
| Operating cash flow | -$105.0M | -$98.1M | -$83.3M | $4.6M | -$11.0M |
| Free cash flow | -$105.9M | -$99.7M | -$85.6M | $3.6M | -$11.2M |
| Diluted shares | 158.2M | 118.5M | 103.4M | 103.1M | 40.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $50.5M | $44.9M | $80.4M | $149.8M | $217.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $2.1M | $8.0M |
| Total debt | $64.8M | $80.8M | $57.5M | $50.0M | $50.5M |
| Total assets | $116.4M | $137.9M | $128.2M | $204.3M | $286.5M |
| Total liabilities | $113.3M | $190.5M | $114.7M | $87.4M | $163.9M |
| Shareholders' equity | $3.1M | -$52.7M | $13.5M | $116.9M | $122.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology